GE Healthcare to power Dr Reddy's biosimilar expansion plans

GE Healthcare today said pharma major Dr Reddy's Laboratories will install a FlexFactory, a single-use manufacturing platform, to expand biologics production capacity at its facility in Hyderabad.
FlexFactory will make Dr Reddy's biopharmaceutical manufacturing set-up more flexible and efficient strengthening the company's position in the global biosimilars market, GE Healthcare said in a statement.
FlexFactory is a centrally automation integrated, flexible biomanufacturing platform. It allows manufacturers to seamlessly establish biopharmaceutical manufacturing capacity within an existing building or as part of a new facility.
"India today has one of the fastest growing biopharma sectors in the world and we are keen to support this development and the production capability of Indian pharma players," GE Healthcare Life Sciences Country Manager, South Asia Milind Palsule said.

The company said the FlexFactory will help Dr Reddy increase its capacity to meet the growth of its currently marketed biosimilars along with launch new biosimilar products in future.